At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
PXT3003 Low dose +3 moredrug
Likely dose
PXT3003 Low dose 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.
In Brief
A Phase 2 clinical trial evaluating PXT3003 Low dose, PXT3003 Intermediate Dose, and 2 other interventions for Charcot-Marie-Tooth Disease and 2 related conditions. Completed, enrolled 80 participants across 6 sites.
Detailed Summary
The present trial is a randomized, placebo-controlled study evaluating 3 different doses of PXT3003 in patients with CMT1A disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCharcot-Marie-Tooth Disease, Hereditary Neuropathy With Liability to Pressure Palsies, Genetic Disorders
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedJul 2011
Primary CompletionOct 2011
Study CompletionDec 2012
TodayJul 2026
First PostedJul 25, 2011
Enrollment StartDec 1, 2010
Primary CompletionOct 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.9 years ago
Interventions
PXT3003 Low dosedrug
Liquid,5 ml, twice a day, 12-month treatment
PXT3003 Intermediate Dosedrug
Liquid,5 ml, twice a day, 12-month treatment
PXT3003 High Dosedrug
Liquid,5 ml, twice a day, 12-month treatment
Placeboother
Liquid,5 ml, twice a day, 12-month treatment